EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Pro-Oncogenic Sphingolipid-Metabolizing Enzyme β-Galactosylceramidase Modulates the Proteomic Landscape in BRAF(V600E)-Mutated Human Melanoma Cells

Davide Capoferri iD, Paola Chiodelli, Marzia Corli, Mirella Belleri, Elisa Scalvini, Luca Mignani, Jessica Guerra, Elisabetta Grillo iD, Veronica De Giorgis, Marcello Manfredi, Marco Presta iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241310555 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Davide Capoferri und 10 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy. Hauptthemen laut MEDLINE: Skin Neoplasms, Melanoma, Experimental. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, Department of Excellence - DIMET - Università del Piemonte Orientale, Associazione Italiana per la Ricerca sul Cancro (AIRC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

β-Galactosylceramidase (GALC) is a lysosomal enzyme involved in sphingolipid metabolism by removing β-galactosyl moieties from β-galactosylceramide and β-galactosylsphingosine. Previous observations have shown that GALC may exert pro-oncogenic functions in melanoma and Galc silencing, leading to decreased oncogenic activity in murine B16 melanoma cells. The tumor-driving BRAF(V600E) mutation is present in approximately 50% of human melanomas and represents a major therapeutic target. However, such mutation is missing in melanoma B16 cells. Thus, to assess the impact of GALC in human melanoma in a more relevant BRAF-mutated background, we investigated the effect of GALC overexpression on the proteomic landscape of A2058 and A375 human melanoma cells harboring the BRAF(V600E) mutation. The results obtained by liquid chromatography-tandem mass spectrometry (LC-MS/MS) demonstrate that significant differences exist in the protein landscape expressed under identical cell culture conditions by A2058 and A375 human melanoma cells, both harboring the same BRAF(V600E)-activating mutation. GALC overexpression resulted in a stronger impact on the proteomic profile of A375 cells when compared to A2058 cells (261 upregulated and 184 downregulated proteins versus 36 and 14 proteins for the two cell types, respectively). Among them, 25 proteins appeared to be upregulated in both A2058-upGALC and A375-upGALC cells, whereas two proteins were significantly downregulated in both GALC-overexpressing cell types. These proteins appear to be involved in melanoma biology, tumor invasion and metastatic dissemination, tumor immune escape, mitochondrial antioxidant activity, endoplasmic reticulum stress responses, autophagy, and/or apoptosis. Notably, analysis of the expression of the corresponding genes in human skin cutaneous melanoma samples (TCGA, Firehose Legacy) using the cBioPortal for Cancer Genomics platform demonstrated a positive correlation between GALC expression and the expression levels of 14 out of the 27 genes investigated, thus supporting the proteomic findings. Overall, these data indicate for the first time that the expression of the lysosomal sphingolipid-metabolizing enzyme GALC may exert a pro-oncogenic impact on the proteomic landscape in BRAF-mutated human melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsMelanoma, ExperimentalHumansAnimalsMiceProto-Oncogene Proteins B-rafGalactosylceramidaseSphingolipidsProteomicsChromatography, LiquidTandem Mass SpectrometryMutationCell Line, TumorCutaneous Malignant Melanoma

Stichwörter der Autor:innen

melanomaproteomicsβ-galactosylceramidase

Substanzen

Proto-Oncogene Proteins B-rafGalactosylceramidaseSphingolipidsBRAF protein, human

Autor:innen und Institutionen

  • Unit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
  • Department of Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy.
  • Center for Allergic and Autoimmune Diseases, University of Piemonte Orientale, 28100 Novara, Italy.
  • Consorzio Interuniversitario Biotecnologie (CIB), Unit of Brescia, 25123 Brescia, Italy.

ORCID-Profile: Davide Capoferri, Elisabetta Grillo, Marco Presta

Förderung

  • Italian Association for Cancer Research
  • Department of Excellence - DIMET - Università del Piemonte Orientale
  • Associazione Italiana per la Ricerca sul Cancro (AIRC)
  • AGING Project—Department of Excellence—DIMET, Università del Piemonte Orientale

Zitieren

APA

Capoferri, D., Chiodelli, P., Corli, M., Belleri, M., Scalvini, E., Mignani, L., Guerra, J., Grillo, E., De Giorgis, V., Manfredi, M., & Presta, M. (2023). The Pro-Oncogenic Sphingolipid-Metabolizing Enzyme β-Galactosylceramidase Modulates the Proteomic Landscape in BRAF(V600E)-Mutated Human Melanoma Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241310555

Vancouver

Capoferri D, Chiodelli P, Corli M, Belleri M, Scalvini E, Mignani L, et al. The Pro-Oncogenic Sphingolipid-Metabolizing Enzyme β-Galactosylceramidase Modulates the Proteomic Landscape in BRAF(V600E)-Mutated Human Melanoma Cells. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241310555

BibTeX
@article{Capoferri2023,
  author = {Capoferri, Davide and Chiodelli, Paola and Corli, Marzia and Belleri, Mirella and Scalvini, Elisa and Mignani, Luca and Guerra, Jessica and Grillo, Elisabetta and De Giorgis, Veronica and Manfredi, Marcello and Presta, Marco},
  title = {The Pro-Oncogenic Sphingolipid-Metabolizing Enzyme β-Galactosylceramidase Modulates the Proteomic Landscape in BRAF(V600E)-Mutated Human Melanoma Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241310555}
}
Kostenlos starten →